Adenovirus pneumonia mimicking osimertinib-induced pneumonitis in a patient with advanced NSCLC with EGFR mutation: A case report.
Toru ImaiTatsuya YoshidaYuichiro OhePublished in: Thoracic cancer (2024)
Drug-related pneumonitis (DRP) caused by epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) is a fatal adverse event in patients with EGFR-mutant non-small cell lung cancer (NSCLC). The diagnosis of DRP is based on radiological findings, the temporal association of presentation with the initiation of a systemic therapeutic agent, and the exclusion of other likely causes. Here we report a case in which severe adenoviral pneumonia mimicking DRP occurred during treatment with osimertinib, and osimertinib was successfully resumed after recovery from adenoviral pneumonia.
Keyphrases
- epidermal growth factor receptor
- advanced non small cell lung cancer
- tyrosine kinase
- small cell lung cancer
- drug induced
- case report
- community acquired pneumonia
- interstitial lung disease
- respiratory failure
- high glucose
- diabetic rats
- adverse drug
- intensive care unit
- brain metastases
- systemic sclerosis
- endothelial cells
- gene therapy
- electronic health record